Affiliation:
1. Department of Neuroscience, UConn Health, 263 Farmington Avenue, Farmington, CT 06030-3401, USA.
Abstract
Abnormal accumulation of β-amyloid (Aβ) peptides is a culprit in Alzheimer’s disease (AD); blocking Aβ generation is therefore being explored as a logical approach for AD treatment. Here, we demonstrate that targeted inhibition of β-site amyloid precursor protein (APP) cleaving enzyme-1 (BACE-1) in microglia has unique advantages. When
Bace-1
was deleted in Alzheimer’s 5xFAD microglia, fewer amyloid plaques developed, and this reduction was not due to changes in APP processing but rather to enhanced Aβ clearance, in line with the increase in a microglial gene signature favoring phagocytosis. Moreover, deletion of
Bace-1
in microglia enhances functions of autophagolysosomes and Aβ-induced metabolic reprogramming necessary for Aβ degradation by favoring phosphorylation of mammalian target of rapamycin complex (mTOR) at Ser
2448
and modulating the PI3K–mTOR–HIF-1α signaling pathways. Mice with deletion of
Bace-1
in microglia showed no reduction in long-term potentiation, unlike global deletion of
Bace-1
. Our results suggest that targeted inhibition of BACE-1 in microglia is a superior strategy for AD treatment.
Publisher
American Association for the Advancement of Science (AAAS)
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献